OTCMKTS:NEPHNephros Stock Price, Forecast & News

$7.90

-0.20 (-2.47 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$7.69

Now: $7.90▼

$8.15

50-Day Range

$7.07

MA: $8.04▼

$9.35

52-Week Range

$4.42

Now: $7.90▼

$11.35

Volume3,315 shs

Average Volume16,007 shs

Market Capitalization$71.18 million

P/E RatioN/A

Dividend YieldN/A

Beta0.85

Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Nephros has a potential upside of 102.5% from its current price of $7.90.
Amount of Analyst Coverage
Nephros has only been the subject of 1 research reports in the past 90 days.

2.0 Community Rank

Outperform Votes
Nephros has received 70 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nephros has received 107 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nephros has received 60.45% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote “Outperform” if you believe NEPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nephros does not currently pay a dividend.
Dividend Growth
Nephros does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nephros insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Nephros is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Nephros are expected to grow in the coming year, from ($0.63) to ($0.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nephros is -14.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nephros is -14.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nephros has a P/B Ratio of 8.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:NEPH

Previous SymbolNASDAQ:NEPH

CUSIPN/A

CIK1196298

Webwww.nephros.com

Phone201-343-5202

Debt

Debt-to-Equity Ratio0.26

Current Ratio2.56

Quick Ratio1.86

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.69 million

Price / Sales12.51

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.89 per share

Price / Book8.88

Profitability

EPS (Most Recent Fiscal Year)($0.54)

Net Income$-3,400,000.00

Net Margins-49.93%

Return on Equity-56.37%

Return on Assets-35.17%

Miscellaneous

Employees18

Outstanding Shares9,007,000

Market Cap$71.18 million

Next Earnings DateN/A

OptionableNot Optionable

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

Nephros (OTCMKTS:NEPH) Frequently Asked Questions

How has Nephros' stock been impacted by COVID-19 (Coronavirus)?

Nephros' stock was trading at $7.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NEPH stock has increased by 5.8% and is now trading at $7.9030. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nephros?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nephros.

How were Nephros' earnings last quarter?

Nephros, Inc. (OTCMKTS:NEPH) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The business earned $2.53 million during the quarter. Nephros had a negative return on equity of 56.37% and a negative net margin of 49.93%. View Nephros' earnings history.

What guidance has Nephros issued on next quarter's earnings?

Nephros updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.6-2.6 million, compared to the consensus revenue estimate of $3.12 million.

What price target have analysts set for NEPH?

2 Wall Street analysts have issued 12-month price objectives for Nephros' shares. Their forecasts range from $16.00 to $16.00. On average, they expect Nephros' stock price to reach $16.00 in the next year. This suggests a possible upside of 102.5% from the stock's current price. View analysts' price targets for Nephros.

Has Nephros been receiving favorable news coverage?

Media stories about NEPH stock have been trending positive on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nephros earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutNephros.

Who are some of Nephros' key competitors?

Some companies that are related to Nephros include Iradimed (IRMD), Liquidia Technologies (LQDA), Accuray (ARAY), Westaim (WEDXF), TELA Bio (TELA), Soliton (SOLY), Pulse Biosciences (PLSE), RenovaCare (RCAR), Apyx Medical (APYX), T2 Biosystems (TTOO), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), Venus Concept (VERO), Spectral Medical (EDTXF) and PAVmed (PAVM). View all competitors.

What other stocks do shareholders of Nephros own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nephros investors own include Cytosorbents (CTSO), Iovance Biotherapeutics (IOVA), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX), Energy Transfer LP Unit (ET), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Who are Nephros' key executives?

Nephros' management team includes the following people:

Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
Mr. Andrew Astor, CFO & COO (Age 62)
Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.

What is Nephros' stock symbol?

Nephros trades on the OTCMKTS under the ticker symbol "NEPH."

Who are Nephros' major shareholders?

Nephros' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wexford Capital LP (37.70%), Cowen Prime Services LLC (1.72%), Ingalls & Snyder LLC (1.48%), Essex Investment Management Co. LLC (0.44%) and BlackRock Inc. (0.10%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow. View institutional ownership trends for Nephros.

Which institutional investors are selling Nephros stock?

NEPH stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. View insider buying and selling activity for Nephros.

Which institutional investors are buying Nephros stock?

NEPH stock was acquired by a variety of institutional investors in the last quarter, including Wexford Capital LP, Cowen Prime Services LLC, Essex Investment Management Co. LLC, and BlackRock Inc.. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans, and Oliver J Spandow. View insider buying and selling activity for Nephros.

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $7.90.

How big of a company is Nephros?

Nephros has a market capitalization of $71.18 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe.

What is Nephros' official website?

The official website for Nephros is www.nephros.com.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.

This page was last updated on 6/6/2020 by MarketBeat.com Staff